Investor Letter to Novartis on India Patent Case

NEW YORK, NY///January 18, 2007/// In a letter to Novartis Chief Executive Officer Dr. Daniel Vasella, Members and Associates of the Interfaith Center on Corporate Responsibility (ICCR) today urged Novartis to withdraw a legal challenge to Section 3(d) of the Indian Patent Act, in a case concerning the patent status of the cancer drug Gleevac / Glivec (imatinib mesylate). The case has implications for millions of patients reliant on generic anti-AIDS medicines produced in India.

To read the full letter, please click here.